A Randomized, Open-Label, Parallel-Group, Single-Dose Study to Characterize the Absolute Bioavailability of Reslizumab (220 mg) Following Subcutaneous Administration to Healthy Subjects

NCT01990443 Phase 1 COMPLETED

The primary objective of this study is to assess the absolute bioavailability of reslizumab following administration of a single subcutaneous (sc) dose to healthy non-Japanese participants

Details

Lead sponsor	Teva Branded Pharmaceutical Products R&D, Inc.
Phase	Phase 1
Status	COMPLETED
Enrolment	75
Start date	2013-06
Completion	2014-03

Conditions

• Absolute Bioavailability

Interventions

• Reslizumab IV
• Reslizumab SC

Primary outcomes

• Absolute bioavailability — From baseline to Day 140
  Absolute bioavailability calculated as (AUC0-∞)sc/(AUC0-∞)

Countries

United States